Requirements and Study Design for the Next Proton FLASH Clinical Trials: an International Multidisciplinary Delphi Consensus
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2025.03.047 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Yvonne L B Klaver und 21 weiteren Autor:innen. Beteiligte Einrichtung: HollandPTC, Delft, The Netherlands; Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: y.klav…. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Neoplasms, Organ Sparing Treatments, Proton Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Cancer Society, American College of Radiation Oncology.
Abstract (Originalsprache)
PURPOSE: The FLASH effect, defined as normal tissue sparing while maintaining tumor control with ultra-high dose-rate irradiation, has been demonstrated preclinically in different tumors and tissues. Although the biological mechanisms are unclear, there is a need for clinical trials investigating the value of proton FLASH irradiation (pFLASH). The purpose of this study was to establish an expert consensus regarding prerequisites, study design, and endpoints for the next clinical trials exploring the clinical potentials of pFLASH. METHODS AND MATERIALS: Delphi methodology was used to develop a systematic expert consensus. An international expert panel was composed of 21 clinicians, physicists, and biologists, well-balanced in expertise and geography, using predefined inclusion criteria. Statements were scored on a 5-point Likert scale in 2 rounds of online questionnaire voting. The definition of consensus was set a priori. RESULTS: The response rate was 100% in both rounds. Preclinical in vivo demonstration of the FLASH effect in normal tissue while maintaining tumor response was deemed essential before starting a clinical trial in a specific tumor site. The next clinical pFLASH trials are advised to include adult patients only, with a minimal expected overall survival of 1 year for palliative settings or, preferably, oligometastatic disease in the ablative setting. The pFLASH effect should be studied in a single treatment modality setting with toxicity reduction as the primary endpoint. Recommendations were formulated on the use of clinical targets and organs at risk constraints, requirements for evaluation and reporting, and accuracy levels and pretreatment verification of dose rates. No consensus was reached on the use of multiple beams, multiple fractions, and fraction dose. CONCLUSIONS: There is a need for additional data regarding the influence of fractionation and multiple beam planning. The results of this study can be used to develop roadmaps to guide future clinical trial design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- HollandPTC, Delft, The Netherlands; Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: y.klaver@hollandptc.nl.
- HollandPTC, Delft, The Netherlands; Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
- Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Radiation Oncology, New York Proton Center, New York, New York; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland; Maryland Proton Treatment Center, Baltimore, Maryland.
Förderung
- NCI NIH HHS
- American Cancer Society
- American College of Radiation Oncology
- Swiss Cancer Research Foundation
- AstraZeneca
- National Institutes of Health
- Associazione Italiana per la Ricerca sul Cancro
- Varian Medical Systems
Zitieren
APA
Klaver, Y. L. B., Hoogeman, M. S., Lu, Q. R., Bradley, J. D., Choi, J. I., Ferris, M. J., Grau, C., Guha, C., Lin, H., Lin, L., Mascia, A. E., Moerman, A. M., Poulsen, P. R., Shi, L. Z., Singers Sørensen, B., Tian, S., Vozenin, M. C., Willey, C. D., Zhou, S., …, & Simone, C. B. (2025). Requirements and Study Design for the Next Proton FLASH Clinical Trials: an International Multidisciplinary Delphi Consensus. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.03.047
Vancouver
Klaver YLB, Hoogeman MS, Lu QR, Bradley JD, Choi JI, Ferris MJ, et al. Requirements and Study Design for the Next Proton FLASH Clinical Trials: an International Multidisciplinary Delphi Consensus. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.03.047
BibTeX
@article{Klaver2025,
author = {Klaver, Yvonne L B and Hoogeman, Mischa S and Lu, Q Richard and Bradley, Jeffrey D and Choi, J Isabelle and Ferris, Matthew J and Grau, Cai and Guha, Chandan and Lin, Haibo and Lin, Liyong and Mascia, Anthony E and Moerman, Astrid M and Poulsen, Per R and Shi, Lewis Z and Singers Sørensen, Brita and Tian, Sibo and Vozenin, Marie-Catherine and Willey, Christopher D and Zhou, Sumin and Amos, Richard A and Hawkins, Maria and Simone, Charles B},
title = {Requirements and Study Design for the Next Proton FLASH Clinical Trials: an International Multidisciplinary Delphi Consensus},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2025.03.047}
}
EUVIMED